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 Abstract  
 
Propionic acidemia (PA) is an autosomal recessive inborn error of metabolism 
caused by deficiency of the mitochondrial enzyme propionyl-CoA carboxylase (PCC). 
The disease presents with acute, recurrent and life-threatening crises of metabolic 
decompensation starting from the newborn period. Patients also suffer from multi-organ 
complications, neurological dysfunction, and cardiomyopathy. Despite available 
treatments, disease mortality and morbidity remain elevated and investigation of novel 
and more effective therapies is highly needed. 
I have generated a PA model in medaka fishes (Oryzias latipes) using TALENs 
targeting the pccb medaka gene, encoding one of the subunits of PCC. The pccb
del/del
 
medaka recapitulates the clinical and biochemical phenotype of human patients. 
Affected medaka larvae showed early lethality and severe neurological impairment as 
shown by reduced and abnormal movements. Livers and hearts of pccb
del/del
 larvae 
exhibited increased lipid droplets, likely as a consequence of impaired mitochondrial β-
oxidation. Importantly, pccb
del/del
 larvae showed a significant increase in the levels of 
propionylcarnitine (C3), the biochemical hallmark of the disease. Administration of a 
low-protein diet improved the survival of pccb
del/del
 larvae. Because PCC deficiency 
induces depletion of Krebs cycle intermediates, I investigated the efficacy of an 
anaplerotic therapy in pccb
del/del
 medaka fishes. The anaplerotic therapy comprising 
sodium citrate, ornithine α-ketoglutarate, and glutamine resulted in significant 
improvements of both survival and locomotor activity in pccb
del/del
 larvae. 
Given its small size, easy handling and large number of progeny, the PA medaka 
model is suitable for rapid investigation of novel drugs by large-scale drug screening. I 
have set a drug screening assay on whole fishes using the clinically relevant locomotor 
4 
 
activity as read-out of the assay. This large drug screening has the potential to lead to 
the identification of small molecule drugs already approved for use in humans that have 
the potential to be rapidly translated in clinical applications. 
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List of abbreviations 
 
AAV, adeno-associated virus 
BC, biotin carboxylase  
BCCP, biotin carboxyl carrier protein domains  
CNS, central nervous system 
CoA, coenzyme A 
CPSI, carbamoyl phosphate synthetase I 
CT, carboxyltransferase 
Dpf, days post fertilization 
FDA, Food and Drug Administration 
GFP, green fluorescent protein 
H&E, hematoxylin-eosin 
HRP, horseradish peroxidase 
IHC, immunohistochemistry 
MMA, methylmalonic acidemia 
OKG, ornithine-α-ketoglutarate 
PA, propionic acidemia 
PBS, phosphate buffered saline 
PCC, propionyl-CoA carboxylase 
RFP, red fluorescent protein 
SD, standard deviation 
SE, standard error 
TALEN, transcription activator-like effector nucleases 
wt, wild-type 
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Introduction 
 
Propionic acidemia 
Propionic acidemia (PA) (OMIM 606054) is an autosomal recessive inborn error of 
metabolism, first described in 1961 as “ketotic hyperglycinemia” for the coexistence of 
ketoacidosis and increased levels of glycine in blood and urine [1]. In 1968 a disorder 
characterized by metabolic acidosis and high levels of propionic acid in blood was 
described and indicated for the first time as “propionic acidemia” [2]. Few years later, 
the biochemical basis of the disease was clarified and the identity between “ketotic 
hyperglycinemia” and “propionic acidemia” was established [3, 4].  
The disorder has an incidence of about 1:50,000 to 1:100,000; although the disease 
incidence is variable among different populations, it is higher in Inuit in Greenland and 
in Saudi Arabia, while Japanese people show higher incidence of a mild form of the 
disease [5-9]. 
PA is caused by deficiency of the biotin-dependent propionyl-CoA carboxylase 
(PCC) (E.C. 6.4.1.3), the mitochondrial enzyme that converts propionyl-CoA into D-
methylmalonyl-CoA. Methylmalonyl-CoA is then converted into succinyl-CoA, a 
Krebs cycle intermediate (Figure 1). Propionyl-CoA is the product of the catabolism of 
different metabolites: valine, isoleucine, methionine, threonine (accounting for about 
50% of total propionic acid), odd-chain fatty acids (accounting for about 25%), while 
degradation of cholesterol side-chain seems to be of little quantitative significance [10, 
11]. Propionate is also formed by gut bacteria, accounting for about 25% of total 
production [11].  
PCC is a heterododecamer composed of six α-subunits encoded by the PCCA gene 
and six β-subunits encoded by the PCCB gene [10]. The crystal structure of PCC has 
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been characterized from bacteria Ruegeria pomeroyi and Roseobacter denitrificans [12]. 
PCC is a heterododecamer with a molecular weight of 750 kDa, composed of six β-
subunits forming a central cylindric core and six α-subunits arranged as monomers 
decorating the central hexamer, each of them interacting with a single β-subunit. The α-
subunits interact with the cofactor biotin and contain the biotin carboxylase (BC) and 
the biotin carboxyl carrier protein domains (BCCP), while the β-subunit is responsible 
for carboxyltransferase (CT) activity. The α-subunit also contains a domain responsible 
for interaction between the BC domain and the CT domain of β-subunit that has been 
called BT domain [12]. The β-subunits work as dimers and the active site is located at 
the interface of the two β monomers. Disease-causing mutations usually impair 
substrate binding or catalytic activity or hamper the assembly of the holoenzyme. 
Mutations affecting either PCCA or PCCB gene can cause the disease and 
approximately 60% of cases of PA patients of Caucasian origin harbour mutations in the 
PCCB gene [13-15]. At least 80 different mutations have been described so far both in 
PCCA and PCCB, including missense, nonsense, splicing mutations, small insertions 
and deletions, and large deletion (the latter only for the PCCA gene) [15-17]. 
The spectrum of clinical presentations of PA ranges from severe neonatal-onset to 
mild late-onset disease. The age of onset seems to be related to residual enzyme activity 
and severity of the disease [18]. The most common classic form of PA typically 
presents in the newborn period with acute onset of metabolic decompensation. During 
pregnancy, toxic metabolites are cleared by the maternal placenta, and thus affected 
patients appear healthy at birth, but develop in the first hours or days of life nonspecific 
symptoms including vomiting, refusal to feed, hypotonia, and lethargy. Clinical 
manifestations are due to severe metabolic alterations including acidosis, ketosis, and 
hyperammonemia. If untreated, the disease precipitates in encephalopathy, cardio-
respiratory failure, and death [19]. In patients with later onset, the disease usually 
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presents in the first years of life, more often with an acute metabolic crisis, while less 
common is the diagnosis in patients only manifesting chronic or intermittent symptoms 
[18].  
If they survive the first episode of metabolic decompensation, patients with both  
early- and late-onset forms have a life-long risk of recurrent, potentially lethal, acute 
decompensations that are usually precipitated by fasting, intercurrent illnesses, 
infections, surgery, or other stressful conditions that induce catabolic stress [19]. 
Moreover, in both forms patients can also manifest chronic symptoms and develop 
multi-organ complications. Many affected children present failure to thrive and growth 
retardation; microcephaly has also been observed in about 30% of cases [20, 21]. Even 
if correctly managed, almost all patients have some degree of central nervous system 
(CNS) involvement. Neurological symptoms include hypotonia, seizures, 
developmental delay, cognitive impairment, movement disorders (ataxia, chorea), 
dystonia, and spasticity. Patients can also manifest acute encephalopathy and stroke-like 
episodes called “metabolic strokes” that frequently involve basal ganglia and result in 
movement disorders [20-22]. Relatively common neuroimaging findings accompanying 
neurological degeneration are brain atrophy, white matter and basal ganglia 
abnormalities [21, 22]. Cardiomyopathy is observed in about one third of cases and is a 
life-threatening complication. Although hypertrophic cardiomyopathy is also described, 
patients more often present with dilated cardiomyopathy. The heart involvement may 
also be isolated and may not be related to the severity or the time of onset of the disease. 
ECG abnormalities, including prolonged QT interval, can also be present and increase 
the risk of sudden death [23-25]. Hematological and immunological abnormalities 
including neutropenia, thrombocytopenia, and rarely pancytopenia can be observed in 
PA patients but their frequency has not been estimated [26]. Recurrent pancreatitis 
represent another rare but potentially severe complication of PA [26].  
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Pathogenesis of PA 
 Even if the molecular defect underlying the disease has been known for many years, 
the pathogenesis of multiple biochemical and clinical abnormalities observed in PA is 
still the object of investigations. 
Several metabolites that are undetected or detected at low levels in normal subjects 
are increased in blood and urine of patients with PA. 3-OH propionate, methylcitrate, 
propionylcarnitine, propionylglycine, and tiglylglycine are the biochemical hallmarks of 
PA [10]. They result from accumulation of propionyl-CoA and its by-products as a 
consequence of the enzyme block and activation of alternative pathways, such as 
conjugation of propionate and other metabolites with carnitine and glycine [1, 27]. 
Large amounts of ketones are formed as by-products of metabolites accumulating 
upstream of the enzyme defect, leading to severe and sometimes untreatable metabolic 
acidosis [10]. The hyperglycinemia is due to impaired glycine cleavage caused by direct 
inhibition by propionyl-CoA and other CoA esters of the glycine cleavage enzyme [28]. 
Glycine acts in the CNS as a neurotransmitter and its increased levels may contribute to 
the neurological manifestations.  
Hyperammonemia has been related for a long time to competitive inhibition of N-
acetylglutamate synthase by propionyl-CoA and production of N-propionylglutamate 
instead of N-acetylglutamate with consequent reduction of N-acetylglutamate levels and 
secondary inhibition of carbamoylphosphate synthetase I (CPS I) (Figure 1) [29]. 
However, several evidences suggest that another mechanism may be responsible for the 
hyperammonemia. Reduced levels of glutamate and glutamine [30] result in reduced 
formation of N-acetylglutamate that leads to impairment of the urea cycle and depletion 
of glutamine that can further contribute to the defect of ammonia handling (Figure 1).   
The Krebs cycle is impaired in PA patients because of a number of mechanisms 
including; i) reduced production of succinyl-CoA; ii) propionyl-CoA competes with 
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acetyl-CoA and combines with oxaloacetate in the reaction catalyzed by citrate synthase 
to form methylcitrate instead of citrate, leading to further depletion of essential 
metabolites (oxaloacetate and citrate); iii) methylcitrate is a potent inhibitor of the Krebs 
cycle enzymes citrate synthase, aconitase, and isocitrate dehydrogenase; iv) propionyl-
CoA and other short-chain acyl-CoA inhibit pyruvate dehydrogenase and α-
ketoglutarate dehydrogenase [31, 32]. In summary, the defect of the Krebs cycle is both 
the consequence of depletion of essential metabolites and enzyme inhibition by toxic 
metabolites (Figure 1).  
It has been hypothesized that in PA patients the Krebs cycle could be replenished by 
increased production of α-ketoglutarate deriving from increased deamination of 
glutamine and glutamate that results from a shift in the equilibrium of the reactions 
catalyzed by glutamate dehydrogenase and glutaminase. This leads to depletion of the 
glutamine/glutamate pool and increased ammonia formation (Figure 1) [33]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of the main metabolic pathways involved in PA. Propionyl-CoA is 
the product of the catabolism of some amino acids, odd chain fatty acids and cholesterol side-chain. The 
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PCC defect causes reduced supply of succinyl-CoA to the Krebs cycle and accumulation of propionyl-
CoA that in turn interferes with several enzyme reactions. In particular, competition with acetyl-CoA in 
the reactions catalyzed by citrate synthase (CS) and N-acetylglutamate synthase (NAGS)  leads to 
reduced production of citrate (replaced by the toxic metabolite methylcitrate) and reduced supply of 
carbamoylphosphate to the urea cycle, respectively. Increased conversion of glutamate into α-
ketoglutarate (to replenish the Krebs cycle) could explain the reduced level of glutamate and glutamine 
that are observed in PA patiens. OAA, oxaloacetate; CS, citrate synthase; NAGS, N-acetylglutamate 
synthase; CPS1, carbamoylphosphate synthetase 1; PCC, propionyl-CoA carboxylase. 
 
Moreover, multiple evidences suggest a defect in mitochondrial energy metabolism 
in PA patients. Krebs cycle impairment leads to reduced production of ATP and 
reduced supply of NADH and FADH2 to the mitochondrial electron transport chain. In 
addition, secondary inhibition of several complexes of mitochondrial electron transport 
chain has been observed both in vivo and in vitro [25, 32, 34-38]. Impaired energy 
metabolism can explain multi-organ toxicity, particularly in tissues that are highly 
dependent on oxidative phosphorylation for energy production like brain, heart, and 
skeletal muscle. The occurrence of neurological and cardiac diseases even in the 
absence of metabolic decompensation suggests the involvement of local production of 
toxic metabolites or defect in energy production [25, 34, 39, 40]. In addition, reduced 
permeability of the blood brain barrier to dycarboxylic acids, with “trapping” of toxic 
metabolites in the CNS has been proposed to explain the neurologic damage [41, 42].  
 
Treatment strategies for PA: state of the art 
Without proper diagnosis and interventions, the prognosis of early onset disease is 
very poor with a mortality close to 100% [43]. In the last few years, there have been 
significant improvements in early diagnosis by expanded newborn screening based on 
C3-propionylcarnitine measurement by tandem mass spectrometry. However, treatment 
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of PA is challenging and even if current treatments have significantly improved long-
term survival, the mortality of the disease remains still high and neurological sequelae 
are common [44].  
Current therapies aim at reducing the production of propionyl-CoA from protein 
catabolism (low protein/high energy diet, avoidance of fasting and stressful events), 
reducing production of propionate by gut bacteria through antimicrobial drugs, and 
increasing propionyl-CoA excretion by carnitine administration [45, 46]. Carnitine 
supplementation is also given to compensate for secondary carnitine deficiency and 
preserve the free acyl-CoA pool. Treatment with the PCC enzyme cofactor biotin has 
been proposed although its efficacy has not been demonstrated [46]. Since 
hyperammonemia is related to inhibition of CPS I, administration of N-
carbamylglutamate, a CPS I activator, is also used for treatment of hyperammonemia in 
PA. Administration of N-carbamylglutamate in PA patients has resulted in increased 
urea production and reduction of ammonia levels [47]. Nevertheless, even a careful 
dietetic and therapeutic management is not able to prevent life-threatening metabolic 
crisis and multi-organ complications. 
Orthotopic liver transplantation is considered particularly in PA patients with 
frequent metabolic decompensations and poor response to dietary and pharmacological 
treatments [46]. Reduction of the frequency and intensity of the metabolic crises as well 
as positive effects on neurological and cardiac complications have been observed in 
patients who received liver transplantation [48, 49]. However, it is still unclear whether 
liver transplantation might prevent the metabolic strokes because of reports of metabolic 
strokes in transplanted patients [49]. Although the liver transplant restores enzyme 
function in liver, PCC remains deficient in the other tissues were it is expressed. 
Although current elective transplant procedures have significantly improved, liver 
transplantation remains an invasive procedure, with its own mortality and morbidity 
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related to rejection and other possible complications and to the need for life-long 
immunosuppression. 
Gene therapy is a promising therapeutic approach for many inborn errors of 
metabolism including PA but there are also several obstacles preventing its application 
in the clinics. PA has often an acute onset in the first days of life, leading to the need for 
a rapid therapeutic intervention and the onset of gene expression by AAV-mediated 
gene transfer is not sufficiently rapid to correct the metabolic acidosis with acute onset 
in the newborn. In case of early administration, liver growth results in loss of episomal 
vector genomes and this will require vector re-administration that is hampered by the 
immune response against the viral vector. Indeed, loss of episomal AAV vector 
genomes as a consequence of liver growth has been observed in several studies [50, 51] 
and compromises long term correction of the phenotype. Moreover, early gene therapy 
administration in newborn mice has been associated to a potential risk of genotoxicity 
and hepatocarcinoma [52-54]. In particular, this finding has also been observed after 
early AAV gene therapy administration in the mouse model of methylmalonic acidemia 
(MMA), a disease biochemically and clinically related to PA due to the deficiency of 
the enzyme downstream of PCC [52]. Although the issue of insertional carcinogenesis 
in humans is still debated, the risk of cancer remains a concern particularly with vector 
administrations in the newborn period. Last but not least, PA is a multi-organ disease 
and it is unclear whether liver-directed gene therapy might result in resolution of all 
disease complications.  
 
Animal models of PA 
Two mouse models of PA have been generated thus far. The first is a Pcca-knockout 
mouse resulting in a severe phenotype and death in the first hours of life for 
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ketoacidosis. For the early lethality, this mouse is not suitable for investigation of the 
disease and experimental treatments [55]. To overcome these limitations, a transgenic 
mouse bearing a mutated human PCCA gene that encodes for an enzyme with reduced 
activity on the background of the Pcca-knockout mouse has been generated. This mouse 
survives into adulthood and thus, it is more suitable for therapeutic investigations [56], 
including the gene therapy [57, 58]. 
 
Open research questions and unmet medical needs 
Available treatments for PA are unsatisfactory and despite therapy, patients still 
suffer from severe and invalidating complications and remain at risk of life-threatening 
metabolic crisis. Therefore, there is a high need for other therapies to be rapidly 
introduced in the clinics to improve the clinical outcomes of patients with PA. With this 
goal in mind, my thesis project has been focused on generating a fish model of PA for 
investigation of small molecule drugs for the treatment of the disease. Searching for 
drugs by high-throughput screening in animal models requires a large number of 
animals and is extremely expensive and unpractical in mice. Conversely, small fishes 
can be easily handled, are available in large number at low costs, and thus are suitable 
for high-throughput drug screening on whole animals. They have both the advantages of 
the small size and the substantial similarity with humans [59-61]. Over the past decades 
fish models have been largely used to investigate developmental processes and more 
recently, they have also shown to be effective in modelling inborn errors of metabolism, 
such as maple syrup urine disease, multiple acyl-CoA deficiency and Menkes disease 
[62-67].  
As a fish model for PA, I have chosen the Japanese medaka fish (Oryzias latipes), a 
small teleost. Compared to zebrafish that have been more widely used, medaka fishes 
have the advantages of being easier to handle, they can develop at a wider range of 
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temperatures, and have a smaller, less redundant and well-draft genome of about 800 
Mb [68]. They have been already used to model several human diseases and relevant 
human phenotypes have been recapitulated, demonstrating similarity in molecular 
pathways and physiological processes [69-73]. 
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Aims of the project 
 
 My project had two main objectives: 
- Specific aim 1: to generate and characterize a medaka fish model of PA.  
- Specific aim 2: to investigate new therapeutic strategies for PA. 
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Methods 
 
Animal strain and maintenance 
Cab strain Oryzias latipes were kept in recirculating water aquaria at 28°C on a 
12/12 h light/dark cycle. Embryos were collected by natural spawning and raised in 
Yamamoto solution at 26°C. All procedures on living animals were performed in 
anaesthesia by administration of tricaine mesylate (MS-222, Sigma Aldrich). Fishes 
were sacrificed by administration of a lethal dose of anaesthetic. All fish studies were 
conducted in accordance with the institutional guidelines for animal research. 
   
Generation of PA medaka 
I used custom-designed transcription activator-like effector nucleases (TALEN) to 
induce targeted mutagenesis in either pcca or pccb medaka genes. TALENs have been 
previously used successfully in medaka for targeted-mutagenesis in disease-causing 
genes [74, 75]. Genomic sequence of medaka pcca and pccb genes was retrieved from 
the Ensembl medaka genome browser (http://www.ensembl.org/Oryzias_latipes) and 
potential TALEN target sites in exon 4 of pcca gene and in exon 3 of pccb gene were 
identified using TALEN Targeter program at https://tale-
nt.cac.cornell.edu/node/add/talen [76]. For pcca, the left (L) and right (R) recognition 
sequences and the spacer sequence were the following: L1 recognition sequence (16 
bp): CGCTGTGAACCGCTATG; R1 recognition sequence (17 bp): 
GATCAAGACCTGTAAG; spacer sequence (17 bp): GTCTGGATGCCCATCCT 
(Figure 2). For pccb gene, the following recognition sequences were identified: L1 
recognition sequence (18 bp): TCCCGGAGACAGCGTGGT; R1 recognition sequence 
(18 bp): AAACCAGCCTGCCGTTAA; spacer sequence (17 bp): 
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GACAGGCCGTGGCAGGA (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Genomic organization of pcca and pccb medaka genes and TALEN target sequences: 
recognition sequences are highlighted in green and spacer sequences are in yellow. 
 
Custom-designed TALEN vectors were assembled by ZGenebio (ZGenebio Biotech 
Inc, Taiwan). For each target gene, two plasmids were produced, each one encoding a 
FokI nuclease monomer and a TAL recognition domain able to recognize the left or 
right recognition sequence, respectively. The left (L) and right (R) plasmids (pZGB-3L 
and pZGB-3R) also included a SP6 promoter, an ampicillin-resistance gene, and a 
cDNA encoding the green or red fluorescent protein. Competent DH5α bacteria were 
transformed with the two plasmids and 500 ml of bacterial suspension, deriving from a 
single clone, was grown in medium containing ampicillin for plasmid preparation. 
Linearized NotI plasmids were extracted from agarose gel using a commercial kit 
(QIAquick Gel Extraction Kit, QIAGEN). RNA was synthesized in vitro using a 
commercial kit (mMESSAGE mMACHINE SP6 Transcription Kit, Ambion, Life 
Technologies).  
A pair of TALEN RNA for each target gene was injected into fertilized eggs at about 
19 
 
1-2 cell-stage, at a concentration of 100 ng/μl by microinjection method [77]. Injected 
embryos were selected on the basis of GFP/RFP expression indicating successful 
translation of the injected RNA. 
After hatching, a sample of more than 20 larvae were sacrificed and lysed for 
genomic DNA extraction. The target region on pcca and pccb gene was amplified by 
PCR and sequenced to determine the presence of TALEN-induced genomic changes in 
mosaic state. Primers for PCR amplification of the target sequences were the following: 
CACAGAGGTGAAGGAAAGTTG (for) and GCAGGTTCCACCTACTATTGAG 
(rev) for pcca gene; GAGCTCAGTTCTGTTCTGCAG (for) and 
GCACAGAAGATCTGTAAGGTGAG (rev), for pccb gene. G0-generation fishes 
(deriving from TALEN-injected embryos) and G1-generation fishes were genotyped 
using the genomic DNA extracted from the caudal fin. G0 mosaics were selected and 
mated with wild-type (wt) fishes to obtain heterozygous animals.  
 
Phenotyping of PA medaka fishes 
External features, heart rate and death were evaluated by direct observation with a 
stereomicroscope (Leica M205 FA). For most experimental procedures, affected larvae 
were selected by external phenotype and then cut into two halves. The caudal half was 
used for genomic DNA extraction and genotype confirmation by PCR and restriction 
digestion by BsaJI enzyme (New England Biolabs Inc). Cranial halves, including the 
head and all internal organs, were used for experiments.  
Survival was evaluated daily by direct observation. Death was established when 
absence of any reaction to repeated mechanical stimulation, as well as absence of heart 
beat for at least 10 s were observed. Total length and heart axis were measured on larval 
bright-field sagittal view, while head diameter was measured on dorsal view. Images 
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were acquired by stereomicroscope and analyzed by ImageJ software 
(www.imagej.net). Histologic examinations were performed on larvae fixed overnight 
in 4% paraformaldehyde/PTW (phosphate buffered saline (PBS)/Tween). For 
hematoxylin-eosin (H&E) staining, I used 4-µm sections obtained after dehydration 
with ethanol and paraffin embedding. For Oil Red staining, fixed larvae were 
dehydrated with cold sucrose and embedded in cryo embedding medium. 8-µm sections 
were cut and stained with Oil Red working solution, as previously described elsewhere 
[66].  
 
Pccb protein studies 
Pccb immunohistochemistry (IHC) was performed on 4-µm sections obtained from 
paraffin-embedded larvae using a rabbit polyclonal anti-pccb antibody (abcam ab96729) 
on at least 3 samples per group (pccb
del/del
, wt). For western blot analysis, larval cranial 
halves were pooled and lysed in RIPA buffer (50 mM pH 7.4 Tris, 150 mM NaCl, 1% 
Triton, 1 mM EDTA, 0.1% SDS) with protease inhibitor cocktail (Sigma Aldrich). Fifty 
micrograms of proteins for each sample were loaded into 10% sodium dodecyl sulfate 
polyacrylamide gel. After transfer to nitrocellulose membrane, blots were blocked with 
Tris-buffered saline-0.1% Tween 20 containing 5% bovine serum albumin (Sigma 
Aldrich) for 1 hour at room temperature, followed by incubation with primary antibody 
overnight at 4°C. The primary antibody was the same rabbit polyclonal anti-pccb 
antibody used for IHC (abcam ab96729). A mouse anti-β-actin antibody was used for 
normalization (Novus Biological). Anti-rabbit IgG-HRP or anti-mouse IgG-HRP (GE 
Healthcare) were used as secondary antibodies for detection and the blot were 
visualized using chemiluminescence. 
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Biochemical analysis 
Larval cranial halves were pooled and lysed in PBS by tissue lyser. After 
centrifugation at 13,200 revolutions per minute for 15 min the supernatant was used for 
measurement of protein concentration and acylcarnitine analysis by tandem mass 
spectrometry performed by the MGL Laboratory at Baylor College of Medicine 
(Houston, Texas, US). Caudal halves were used to confirm the genotype, as described 
above.  
 
Behavioral analysis 
Live video tracking of medaka larvae was performed using DanioVision system 
(Noldus Information Technology, Leesburg, VA). 12 to 14 days post fertilization (dpf) 
larvae were chosen for this analysis because at this stage the abnormal phenotype was 
evident in almost all homozygous animals and this allowed their selection. Larvae were 
placed into 96-well plates, each well containing 150 μl of raising water, and introduced 
into the DanioVision observation chamber. The chamber includes an infra-red sensitive 
camera, a programmable white light source and a camera lens for an optimal image of 
all wells without angular distortion. Locomotor activity was evaluated after a 10-min 
acclimatization period to reduce anxiety-like behaviour. The EthoVision XT Software 
was used to analyze video tracks [78]. The thresholds for movement detection were 0.2 
mm/s (start velocity) and 0.1 mm/s (stop velocity). For basal movement analysis, larvae 
were tracked over a 20-min light period and tracks were analyzed for total distance 
moved (mm) and movement cumulative duration (s). For analysis of motor response 
after light stimulation, larvae were kept in total darkness for 20 min before stimulation 
with the maximum light intensity. Movement parameters were measured over the 60 s 
following the light stimulation. 
22 
 
Treatments on affected larvae 
 Glucose and drugs were all added to the raising water. Larvae were raised in 6-well 
plates, and the water was changed every day. Treatments were performed since 
hatching. With the exception of the experiments with the low-protein diets, larvae were 
fed with standard fish food (Tetramin, Tetra, Spectrum Brands Company). The low 
protein diets containing either 15% or 30% of proteins were custom-made and provided 
by the USDA Agricultural Research Service, Bozeman, MT, USA. For all drugs, scalar 
concentrations were first administered to wt larvae to establish the maximum tolerated 
concentration in the absence of toxicity. The maximum tolerated concentration was used 
for treatment of PA larvae. The final concentration was 1 mM for antipyrine, 10 µM for 
carnitine, ornithine α-ketoglutarate (OKG) and sodium citrate, and 1 µM for glutamine. 
Antipyrine, carnitine, glutamine, and sodium citrate were all purchased by Sigma-
Aldrich, and OKG from Bulkpowders. For survival analysis, larvae were all raised until 
30 dpf; at dpf 30 all larvae were sacrificed and the cumulative survival during the 
observation period was calculated.  
 
Drug screening 
 Movement analysis performed with the DanioVision system was used as first-line 
screening test. Total distance moved and movement cumulative duration were used as 
read-outs. The analysis was performed both in basal conditions (20 min) and after light 
stimulation (1 min). Larvae were placed in 96-well plates: 80 wells out of 96 contained 
pccb
del/del
 larvae used to test 80 different compounds. Compounds were added to the 
raising medium at 10 µM concentration and robotically dispensed into single wells. The 
remaining 16 wells in each plate contained only raising medium, and were used as 
internal controls: 8 with wt larvae (positive controls) and 8 with non-treated pccb
del/del
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larvae (negative control). Each plate was analyzed in triplicate. Movement analysis on a 
larger number of larvae (≥8) was performed as second-line screening. Hits passing the 
second-line screening were evaluated for their effect on survival. 
For hits selection, I compared movement parameters between larvae treated with the 
investigational compounds and untreated larvae (negative controls). To this aim, for 
each compound I used results obtained from three independent experiments on single 
larvae. To pool results, I first normalized values from each plate on the basis of mean 
values from positive and negative controls. For each compound, means of normalized 
values obtained from the three experiments were compared with the mean of negative 
controls by 1-sided T-test. Those compounds showing significant improvement 
(p<0.05) for at least one movement parameter (compared to untreated pccb
del/del
 larvae) 
were identified as potential hits.  
 
Statistical analyses 
 T-test and the Fisher’s exact test were used for comparisons between two 
experimental groups and two proportions, respectively. For Kaplan-Meier survival 
analysis, the Log rank Mantel-Cox test was applied. Outliers defined by two-sided 
Iglewicz and Hoaglin's robust test for multiple outliers (modified Z-score: 3.5) were 
excluded in behavioral analyses. 
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Results 
 
Generation of PA medaka 
To evaluate the presence of TALEN-induced mutations, I analyzed the target region 
in medaka larvae deriving from injected embryos.  
I found no mutations in medaka larvae deriving from embryos injected with the pcca 
TALEN. To explain the lack of TALEN-induced mutations, I sequenced the genomic 
DNA extracted from our medaka colony and I detected a synonymous nucleotide 
change (c.204C>T) in the L recognition sequence of the TALEN on the pcca gene. This 
nucleotide change is likely responsible for the lack of recognition and TALEN-induced 
mutations. 
In contrast to pcca, TALEN-induced mutations were found in 8/28 (~28%) larvae 
from pccb TALEN-injected embryos. As expected, I observed multiple mutations in a 
mosaic fashion, starting from position 390 (spacer sequence) (Figure 3A).  
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Figure 3. (A) On the left: starting from nucleotide position 390 of pccb cDNA, the presence of multiple 
peaks underneath the predominant wt sequence (green arrow) suggests TALEN-induced mosaicism. On 
the right: multiple peaks are not visible in wt embryos. (B). TALEN induced mutations (indels) detected 
in larvae by targeting the exon 3 of the pccb medaka gene; inserted and duplicated bases are shown in red. 
 
Germline transmission was not detected in 5/16 of G0 fishes deriving from TALEN-
injected embryos (31.2%). For fishes showing germline transmission, the percentage of 
the offspring carrying pccb mutations ranged from 5% to 40%.  
The analysis of pccb target sequences from G1 heterozygous fishes revealed 10 
TALEN-induced mutations, the most frequent being an in-frame 6-bp deletion 
(c.391_396delCGTGGC) that is predicted to result in loss of two amino acids (R131-
G132). There was only one other in-frame mutation (a duplication affecting the same 
base pairs: c.391_396dupCGTGGC) whereas all the others were frameshift insertions or 
deletions (Figure 3B).  
The amino acids involved in the 6-bp deletion (R131-G132) are conserved in the 
human PCCB gene. Missense and nonsense mutations affecting corresponding amino 
acid residues in the human PCCB protein (R111-G112) have been reported in patients 
with early onset PA [13, 79, 80]. I hypothesized that the in-frame deletion could result 
in a less severe phenotype compared to frameshift mutations. Based on these 
considerations, I selected G1 heterozygous fishes bearing the c.391_396delCGTGGC 
mutation for future studies and therefore they were mated to generate pccb
del/del
 larvae.  
   
Phenotyping of pccb
del/del
 medaka  
I evaluated pccb protein levels by western blot and IHC on homozygous larvae, and I 
observed that the protein was detected in pccb
del/del
 larvae at levels that were similar to 
wt and heterozygous larvae (Figure 4A-B-C) 
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Figure 4. Pccb protein in pccb
del/del
 larvae by western blot 
analysis on a pool of 18-20 larvae (A), and by pccb IHC on a 
sagittal section of a pccb
del/del
 larva (B), that shows 
ubiquitous expression of the protein and increased signal in 
the liver (arrow). A negative control (no secondary antibody) 
is shown in (C). IHC in B and C are representative images of 
at least N = 3. 
 
 
 
 
Homozygous pccb
del/del
 larvae have a delayed mean hatching time (9.8 vs. 8.2 dpf of 
wt larvae), suggesting delayed embryonal development and/or reduction of prenatal 
motility (Figure 5).  
 Figure 5. Mean hatching 
time in homozygous larvae 
compared to wt. Mean±SD; 
wt: N = 30, pccb
del/del
: N = 
47; ***p < 0.001; T-test. 
 
 
 
No remarkable differences in the gross appearance were observed in pccb
del/del
 larvae 
compared with wt larvae with the exception of yolk oedema suggesting inefficient 
reabsorption (Figure 6). The body and head size were mildly reduced, resembling 
growth failure observed in children with PA (Figure 7A-B). 
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Figure 6. External appearance of 14-dpf larvae. The 
yolk oedema is shown by the arrow. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Body length (A) and head diameter (B) of pccb
del/del
 larvae compared with wt. Mean±SD; N=23 
for each group; *p<0.05, ***p<0.001; T-test. 
 
Although cardiomyopathy is observed in human patients, no cardiac enlargement 
was detected in pccb
del/del
 larvae and only a mild increase in the heart rate was detected 
(Figure 8A-B).  
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Figure 8. (A) Heart major axis was measured using stereomicroscope and used as marker of heart 
volume: no difference was observed between pccb
del/del
 and wt larvae. Mean±SD; wt: N = 17, pccb
del/del
: N 
= 16. (B) A mild increase in heart rate was observed in pccb
del/del
 larvae. Mean±SD; wt: N = 23, pccb
del/del
: 
N = 22; *p<0.05; T-test. 
 
Most severely affected pccb
del/del
 larvae showed reduced movements since hatching 
and death in the first days after hatching. Nevertheless, the majority of them presented 
normal at hatching and usually within 7 days from hatching, they showed abnormal 
movements and progressive loss of motility, inability to feed and lethargic state with 
complete lack of activity despite detectable heart beating. Abnormal movements such as 
“corkscrew” movements suggesting neurological impairment were also observed before 
progression of the disease to paralysis. All pccb
del/del
 larvae did not survive beyond 20 
days after hatching whereas less than 5% mortality was observed in heterozygous and 
wt larvae, consistent with previous data in medaka [81] (Figure 9).   
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Figure 9. Kaplan-Meyer survival curve. Homozygous larvae have reduced survival compared to 
heterozygous and wt controls. Wt: N = 23, pccb+/-: N = 49, pccb
del/del
: N = 31; ***p < 0.001; Mantel-Cox 
Log rank test. 
 
Similar to PA patients, pccb
del/del
 larvae did not show any organ malformations as 
determined by microscopic examination of living larvae and by H&E staining 
performed on a total of 25 larvae (12 wt, 13 pccb
del/del
) (Figure 10).  
 
 
 
 
 
 
Figure 10. Hematoxylin-eosin staining on pccb
del/del
 and wt larvae. No abnormalities were detected in 
pccb
del/del
 compared to wt larvae.  
 
Since fatty degeneration of the liver has been described in several historical reports 
of patients with PA [2, 37, 82] and presence of lipid droplets has been observed in the 
livers of the Pcca knockout mouse model of PA [55], I investigated lipid accumulation 
in pccb
del/del
 medaka larvae by Oil Red staining. I observed lipid droplets in the liver of 
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10/14 pccb
del/del
 larvae compared to 1/10 of wt (p<0.01, Fisher’s test) (Figure 11A). 
Moreover, I also observed lipid droplets in the heart of 8/10 affected larvae compared to 
1/8 wt (p<0.05, Fisher’s test) (Figure 11B).  
 
 
 
 
 
 
 
 
Figure 11. Oil Red staining showing lipid accumulation in the liver (A) and in the heart (B) of pccb
del/del
 
larvae, absent in almost all wt larvae.  
 
Biochemical analysis 
To investigate whether pccb
del/del
 larvae recapitulate the biochemical abnormalities 
observed in PA patients, the acylcarnitine profiles on lysates obtained from pools of 
homozygous, heterozygous, and wt larvae were measured by tandem mass 
spectrometry. Homozygous larvae showed a significant increase in the levels of 
propionylcarnitine (C3), the major biochemical marker of the disease in human patients 
(Figure 12).  
Figure 12. Propionylcarnitine levels in 
homozygous, heterozygous and wt larvae 
sacrificed at 11±3 dpf. Each sample is a lysate 
obtained from a pool composed of 18 larvae. 
Results are normalized for protein concentration. 
Mean±SD; N = 3; *p < 0.05; **p<0.01; T-test. 
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Behavioral phenotype 
Affected larvae showed a locomotor defect that ranged from reduction to total lack of 
movements. Automated quantitative analysis of locomotor behavior confirmed 
significant deficiency in movements measured by two parameters (total distance moved 
and movement cumulative duration), during 20 minute-observations under basal 
conditions and 1 minute-observation after light stimulation (Figure 13). Although 
reduced compared to wt fishes, the presence of a startle reaction after light stimulation 
in pccb
del/del
 larvae suggests some preservation of visual function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Movement analysis showing severe reduction of locomotor behavior in pccb
del/del
 larvae 
compared to wt both under basal conditions (A) and after light stimulation (B). Mean±SE; basal 
observation: wt N = 28, pccb
del/del
 N = 25; light stimulation: distance moved wt N = 31, pccb
del/del
 N = 22, 
movement duration wt N = 31, pccb
del/del
 N = 28; ***p<0.001; T-test.  
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Efficacy of low protein diet in PA fishes 
I evaluated the response of PA larvae to a low protein diet aimed at reducing 
propionyl-CoA production. I compared two low protein diets with different protein 
content (15% and 30%, respectively). Larvae fed with the diet with the lowest protein 
content (15%) showed increased survival (Figure 14). This result suggests a toxic effect 
of food proteins, recapitulates a feature seen in PA patients, and supports the validity of 
pccb
del/del
 medaka fishes as a disease animal model of PA. 
Figure 14. PA larvae fed 
with higher protein 
concentration showed 
increased mortality. Wt: 
N = 27, pccb
del/del
: N = 17; 
*p<0.05; Mantel-Cox Log 
rank test. 
 
 
Efficacy of anaplerotic therapy in PA fishes 
Anaplerotic therapy is a treatment aimed at improving energy metabolism by 
replenishing Krebs cycle metabolites. Anaplerotic therapy in PA patients has been 
proposed [33]. However, there are no evidences either in clinical or preclinical studies 
supporting its efficacy for therapy of PA. Therefore, I investigated an anaplerotic 
therapy composed of sodium citrate, OKG and glutamine in pccb
del/del
 fishes. The 
anaplerotic therapy was administered either alone or in combination with carnitine (the 
drug given to PA patients to increase propionic acid excretion) and glucose (as a non-
protein source of energy). In both cases, larvae treated with the anaplerotic therapy 
showed a significant improvement of survival (Figure 15A-B). Moreover, a significant 
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improvement in movement parameters was detected in larvae treated with anaplerotic 
therapy (Figure 15C-D).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. (A) pccb
del/del
 larvae showed significant increased survival after administration of anaplerotic 
therapy. No drug: N = 30, anapl. ther.: N=15; **p<0.01; Mantel-Cox Log Rank test. (B) Anaplerotic therapy in 
combination with glucose and carnitine improved survival compared to glucose and carnitine. Glucose plus carnitine: 
N = 23, anapl. ther. plus glucose and carnitine: N =40; ***p<0.001; Mantel-Cox Log rank test. (C-D) pccbdel/del larvae 
treated with anaplerotic therapy showed significant increase in locomotor activity both under basal conditions (C) and 
after light stimulation (D). Mean±SE; no drug: N  =  5, anapl. ther.: N = 13; *p<0.05**p<0.01; ***p<0.001; T-test.   
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High throughput drug screening in pccb
del/del
 fishes 
The PA medaka model is a suitable animal model for large-scale drug screening. 
With the goal of performing a high throughput drug screening in pccb
del/del
 fishes, I set 
up the assay for the screening and began the evaluation of a subset of drugs from the 
Prestwick Library that is composed of 1280 Food and Drug Administration (FDA)-
approved drugs. The preliminary screening was performed on the first plate (80 
compounds). 
After the first-line screening, I identified 14 positive hits that correspond to 
compounds that improved at least one movement parameter compared to negative 
controls (untreated larvae). To avoid false positive hits, I performed the screening in 
triplicate and I selected drugs that showed efficacy in all three experiments. In the initial 
screening three compounds (antipyrine; dapsone; sulpiride) were found positive and 
were evaluated for the second-line screening in a larger number of larvae (≥8) (Figure 
16). The improvement by sulpiride and dapsone was not confirmed on the second-line 
screening whereas antypyrine was confirmed to be effective at improving the movement 
behaviour. 
 
 
 
 
 
 
 
Figure 16. Second-line screening by movement analysis over a 20-min observation period in basal 
conditions. pccb
del/del
 larvae incubated with antipyrine showed improvement in one parameter. Mean±SE; 
no drug:  N = 8, dapsone: N = 9, antipyrine N = 8; *p<0.05; T-test.  
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 Finally, I evaluated survival of larvae treated with antipyrine, but I did not observe a 
significant improvement in treated larvae compared to untreated (Figure 17). Therefore, 
the antipyrine does not appear to affect the natural progression of the disease in fishes. 
 
Figure 17. No 
improvement in 
survival was observed 
in pccb
del/del
 larvae 
treated with antipyrine, 
compared to wt. No 
drug: N = 31, 
antipyrine: N = 19.   
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Discussion 
 
 PA is a severe disease presenting with life-threatening metabolic decompensations 
and multi-organ involvement. Effective therapies are still not available and patients 
continue to be at risk of developing lethal metabolic crisis and invalidating 
complications.  
The available mouse model is a valuable tool for investigating experimental 
therapies. However, it is not suitable for large drug screening.   
An ideal treatment for PA should be sufficiently safe and ready to be administered in 
the newborn period or even prenatally if a prenatal diagnosis of PA is made. Moreover, 
it should be effective in correcting disease manifestations in different organs. A high-
throughput drug screening is an attractive approach to rapidly investigate a large 
number of drugs in vivo. The small fishes give the unique possibility to perform such an 
in vivo high-throughput drug screening. Therefore, for this thesis project I generated a 
medaka model of PA and set the conditions for the use of this model for therapeutic 
investigations and drug screening.  
 To generate knock-out fishes, I used TALEN technology, a genome editing strategy 
with high efficacy and specificity for the targeted region. Among the embryos targeted 
in pccb, I chose those bearing the in-frame deletion with higher chances to result in a 
non-lethal phenotype. The deletion involves the residues R131-G132 of the pccb protein 
and by comparison with the human PCCB sequence these residues (corresponding to 
human R111-G112 amino acids) are located in a conserved region.  
Based on the analysis performed by Huang et al. on the bacterial PCC, the G112D 
mutation described in PA patients was located in the β-subunit in a region near to the 
interface with the α-subunit, and the amino acid change was thought to determine 
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disruption of the β-subunit integrity because of the introduction of the aspartate side 
chain [12]. Indeed, human fibroblasts with the G112D mutation showed almost 
undetectable PCC activity and reduced to absent Pccb protein, in the presence of normal 
mRNA levels [13, 83]. In pccb
del/del
 fishes I observed levels of pccb protein comparable 
to wt, indicating that the mutant protein is stable and not subjected to early degradation. 
On the basis of the structural characterization of the protein I can therefore hypothesize 
that the amino acids deletion, located in a region near the interface with the α-subunit, 
could hamper the interaction with the α-subunit, without disrupting the integrity of the 
β-subunit.  
Patients with PA are usually normal at birth and the disease only manifests in the 
postnatal period. In contrast, affected larvae showed a delay in the hatching time that 
may suggest an impaired embryonal development. Early onset of energy deficiency 
leading to movement impairment may be the result of early accumulation of toxic 
metabolites. Compared to the intrauterine prenatal development of humans, medaka 
have an external embryo development and residual maternal RNA does not last more 
than 48-72 h post fertilization. Therefore, medaka might suffer from the toxic effects of 
PA metabolites at earlier stages.  
The phenotype of pccb
del/del
 larvae resembles the severe early-onset PA. Untreated 
children with early-onset PA have 100% mortality in the first years of life.  PA patients 
are substantially normal in their appearance, except for possible growth failure and 
microcephaly. Similarly, affected larvae did not show organ malformations or gross 
differences in external appearance, but only very mild reduction in their mean body 
length and head diameter. The reduced growth was observed in the first days after 
hatching, and thus, it is not the result of impaired feeding. Affected larvae showed yolk 
retention, an indicator of development delay and a known sign of toxicity in both 
medaka and zebrafish. According to some authors it is a sign of liver toxicity [84-86].  
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Fatty degeneration of the liver has been described since the first reports in patients 
with severe PA [2, 37, 82]. Hypothesis explaining this finding include inhibition of fatty 
acids β-oxidation due to toxic metabolites and increased synthesis of odd-chain fatty 
acids. Indeed, impaired oxidation of 
14
C-palmitate by propionic acid has been observed 
[27] and could be due both to direct enzyme inhibition by toxic metabolites and reduced 
carnitine and free acyl-CoA pool. On the other hand, propionyl-CoA acts as a primer for 
odd-chain fatty acid synthesis and increased amount of odd-numbered long chain fatty 
acids has been observed in erythrocytes from patients with PA [87]. Lipid droplets have 
been also observed in the liver of the Pcca knockout mouse model of PA [55] and 
reduced expression of β oxidation enzyme hydroxyacyl-coa dehydrogenase has been 
detected in liver, muscle, and heart of the Pcca-/- mouse [38]. Consistent with these 
data, I observed presence of lipid droplets in pccb
del/del
 larvae. Increased lipid staining 
was also present in the heart. This is consistent with the high β-oxidation activity of the 
heart. However, no alterations of heart volume and morphology were detected in 
pccb
del/del
 larvae. A very mild increase in the heart rate is a rather non-specific sign.  
 The markedly increased levels of propionylcarnitine which is the biochemical 
hallmark of the disease, makes the medaka model similar to humans and supports the 
validity of the fish as a disease model. Further confirmation for the validity of the model 
came from the response to low protein diet that improved survival.    
 CNS is one major organ affected in PA and almost all patients have some degree of 
neurological or cognitive impairment. The locomotor activity in small fishes reflects 
their neurologic status. Homozygous larvae indeed showed signs of neurological 
impairment such as severe reduction of movements and abnormal movements like 
“corkscrew” swimming, suggesting a seizure phenotype [88]. The progression towards 
a lethargic state preceding death also resembles the late evolution of the PA phenotype 
in untreated neonatal-onset patients. 
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 Once the PA medaka fishes were generated, I used them to investigate a specific 
therapy and to validate them for high-throughput drug screening.  
The metabolic derangement underlying PA is the result of both accumulation of toxic 
metabolites and impaired energy metabolism due to depletion of Krebs cycle 
intermediates and inhibition of mitochondrial electron transport chain. Anaplerotic 
therapy is aimed at providing substrates to the Krebs cycle. Triheptanoin, an odd-carbon 
triglyceride, has been administered as precursor of acetyl-CoA and propionyl-CoA in 
patients with pyruvate carboxylase deficiency, carnitine palmitoyltransferase II 
deficiency and long-chain fatty acids oxidation defects, with good clinical outcomes 
[89-92]. Administration of PA precursors will worsen PA but anaplerotic therapy 
supplying Krebs cycle intermediates and their precursors has potential to be effective. 
PA indeed results in Krebs cycle impairment due to enzyme inhibition and depletion of 
intermediates, as well as depletion of the glutamate/glutamine pool. Therefore 
supplementation with α-ketoglutarate and sodium citrate plus glutamine could improve 
the Krebs cycle (Figure 18) [33].  
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Figure 18. Schematic representation of the rationale for the anaplerotic therapy in PA. Krebs cycle 
impairment is caused by deficient production of succinyl-CoA and citrate, as well as direct inhibition of 
several enzymes. To provide α-ketoglutarate to the Krebs cycle, reactions catalyzed by glutamate 
dehydrogenase and glutaminase are shifted towards deamination of glutamate and glutamine, with 
depletion of the glutamate/glutamine pool. Administration of ornithine-α-ketoglutarate, glutamine and 
sodium citrate (in green) could contribute to replenish the Krebs cycle, improve energy production and 
reduce catabolism.  
 
Because a detrimental consequence of energy deficiency in PA is the lack of ATP 
production leading to activation of catabolic pathways (likely through AMP kinase) that 
in turn causes further production of toxic metabolites, it can be hypothesized that 
inducing a shift towards anabolism would be beneficial [89]. For this reason, ornithine 
was administered together with α-ketoglutarate with the goal of stimulating anabolism. 
Ornithine is conjugated in form of salt to α-ketoglutarate (OKG), in a 2:1 molar ratio, 
because it has been demonstrated that the simultaneous administration of these two 
metabolites in this ratio shifts the metabolism of ornithine towards arginine formation, 
providing an important stimulus to anabolism [93]. OKG has been used for years in 
patients with several conditions for its beneficial actions on nutritional status, wound 
healing and immune system [93]. Although the use of anaplerotic therapy has been 
proposed for several years [33], its efficacy has never been proved neither in human 
patients with PA nor in animal models. 
The anaplerotic therapy significantly improved both survival and locomotor 
behaviour of PA larvae, suggesting that it is a promising therapy for PA.  
Finally, I set up a screening assay for drug discovery in the PA medaka model and I 
evaluated the first 80 compounds of the Prestwick Library. The use of whole animals 
for screening and locomotor behaviour as read-out have the advantage of overcoming 
the in vitro analyses and to immediately test drugs based on their effect on clinically 
relevant endpoints. One limitation of this analysis is the variability in movement 
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parameters in affected larvae. However, performing the first-line screening in triplicate 
and the second-line screening on a larger number of larvae can overcome this limitation. 
After a first-line screening on a limited number of compounds, I selected three potential 
hits, and one of them (antipyrine) was confirmed in the second-line screening, resulting 
in a mild effect on movement. This drug did not result in effects on survival and 
therefore did not affect the natural history of the disorder. Nevertheless, it may still be 
an effective treatment that might lead to some degree of amelioration and requires 
further investigation. Finally, I have set the conditions for the screening of the whole 
drug library. The use of the Prestwick Library composed of FDA-approved drugs has 
the advantage of being rapidly transferred to the bedside without the need of expensive 
and time-consuming toxicity studies. 
 
 In summary, I generated a medaka model of PA that recapitulates the main clinical 
and biochemical features of the disease and is a valuable tool for therapeutic 
investigation. I have tested the efficacy of anaplerotic therapy, a treatment with high 
potential for clinical translation and I have set the conditions for a high-throughput drug 
screening on whole animals that could lead to the identification of effective drugs for 
therapy of PA.  
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